文献速递肺外科

非小细胞肺癌隐匿性N1/N2淋巴结转移:肺段切除与肺叶切除临床结局相当的多中心真实世界研究

Comparable Clinical Outcomes Between Segmentectomy and Lobectomy for NSCLC With Unsuspected N1/N2: A Multicenter Real-World Data Study.
PubMed 文献 · Ann Thorac Surg · 2025-03-20

该多中心真实世界研究纳入2012至2021年间临床T任何期N0、术后病理证实N1或N2淋巴结转移的非小细胞肺癌患者,比较肺叶切除(736例)与肺段切除(70例)的结局。倾向性评分校正后两组总生存、无复发生存及累积复发率无显著差异,但肺段切除组局部复发率更高。提示此类患者或无需追加剩余肺段切除,但需警惕局部复发。

要点

  • 倾向评分校正后肺段切除与肺叶切除的总生存、无复发生存及累积复发率无显著差异。
  • 肺段切除组局部复发率高于肺叶切除组,需谨慎对待。
  • 结果提示隐匿性N1/N2患者或无需追加切除剩余肺段。

核心结论

  • 在隐匿性N1或N2非小细胞肺癌患者中,倾向评分校正后肺段切除与肺叶切除的总生存、无复发生存及累积复发率无差异,提示或无需追加切除剩余肺段,但肺段切除组局部复发率更高需谨慎考虑。

研究设计与样本

  • 多中心真实世界数据研究,纳入2012至2021年间临床T任何期N0、术后病理诊断为N1或N2淋巴结转移并接受肺叶切除或肺段切除的非小细胞肺癌患者,肺叶切除组736例,肺段切除组70例,采用未校正和倾向评分校正队列分析。

主要发现

  • 未校正队列中肺段切除组患者年龄更大、术前肺活量百分比更低、肿瘤更小且术后辅助化疗更少,5年总生存显著更差(P = .011),5年无复发生存及累积复发率无显著差异。
  • 倾向评分校正队列中两组总生存、无复发生存及复发率无显著差异,但肺段切除组局部复发率更高。

临床怎么用

  • 对于临床N0但术后病理证实隐匿性N1或N2的非小细胞肺癌患者,肺段切除后或无需常规追加剩余肺段切除,但应加强局部复发监测。

局限性

  • 肺段切除组样本量较小(70例),且为真实世界回顾性研究,可能存在选择偏倚和未测量混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Segmentectomy for lung cancer has been increasingly performed. However, evidence regarding the necessity of additional surgical resection after the diagnosis of unsuspected N1 or N2 lymph node metastasis is limited. METHODS: We conducted a multicenter, real-world data study of patients with any clinical T and N0 non-small cell lung cancer (NSCLC) who underwent lobectomy or segmentectomy between 2012 and 2021 and who subsequently received a diagnosis of pathologic N1 or N2 lymph node metastasis. Patients were categorized into lobectomy and segmentectomy groups. We analyzed overall survival (OS), recurrence-free survival (RFS), cumulative recurrence rates, and recurrence patterns using both unadjusted and propensity score-adjusted cohorts. RESULTS: A total of 736 patients were in the lobectomy group, and 70 were in the segmentectomy group. In the unadjusted cohort, segmentectomy-treated patients were older, had a lower preoperative percentage of vital capacity, had smaller tumors, and received less postoperative adjuvant chemotherapy. The 5-year OS was significantly worse in the segmentectomy group (P = .011), with no significant differences in 5-year RFS or cumulative recurrence rates. In the propensity score-adjusted cohort, there were no significant differences in OS, RFS, or recurrence rates; however, the segmentectomy group had a higher rate of local recurrence. CONCLUSIONS: In patients with unsuspected N1 or N2 NSCLC, analysis using a cohort adjusted for patient background with propensity scores revealed no differences in OS, RFS, or cumulative recurrence rates between segmentectomy and lobectomy. This finding suggests that additional resection of the remaining segments may not be necessary for these patients. However, the higher rate of local recurrence in the segmentectomy group warrants careful consideration.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Ryuko T, Okazaki M, Mitsuhashi T, et al. Comparable Clinical Outcomes Between Segmentectomy and Lobectomy for NSCLC With Unsuspected N1/N2: A Multicenter Real-World Data Study. Ann Thorac Surg. 2025. PMID: 40120787. doi:10.1016/j.athoracsur.2025.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。